While previous studies have predominantly identified BCL6 as a hematopoietic tumor-specific oncogene (Kawabata et al., 2021), intriguing emerging data have also linked BCL6 to the regulation of the progression of solid tumors, such as lung cancer (Li et al., 2022), breast cancer (Yu et al., 2015), and ovarian cancer. This evidence concerns the gene BCL6 and ovarian cancer.